Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_03002 |
| Species: | Homo sapiens |
| Position : | chr8:67740000-67741000 |
| Year: | 2018 |
| Title: | Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | hepatocellular carcinoma |
| PMID: | 29113912 |
| MONDO: | MONDO:0007256 |
| Tissue: | liver |
| Tissue Ontology ID: | UBERON:0002107 |
| Cell Source: | Primary Human Hepatocellular Carcinoma Cells |
| Cell Type: | malignant cell |
| Cell Ontology ID: | CL:0001064 |
| Experiment Type: | Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation; In vivo functional validation |
| High Throughput Method: | ChIP-seq, RNA-seq |
| Low Throughput Method: | qRT-PCR, and ChIP-qPCR; ChIP; RT-qPCR; Western blot; shRNA knockdown; Mouse genetic deletion/knock-in; In vivo phenotyping; Xenograft/xenotransplant |
| Target gene : | ANGPT2 |
| TF name : | NA |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|